Concept
Immunotherapy Reach
Cancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute / What the Report Means for Immunotherapy
"The survival gains documented in this report validate decades of investment in cancer immunology. But they also underscore how much work remains:\n\nExpand immunotherapy to more cancer types: While melanoma and lung cancer have seen dramatic gains, many cancers remain resistant to current immunotherapies. The five-year survival rate for pancreatic cancer, for example, remains at just 13%, and uterine corpus cancer mortality has been rising for 26 consecutive years.\n\nEnsure broad access to innovation: Scientific breakthroughs only save lives if patients can benefit from them. The report shows wide variation in cancer incidence and outcomes across the U.S., reflecting geographical differences in prevention, early detection, and availability of high-quality care. Ensuring that advances in immunotherapy and precision medicine reach patients everywhere remains a critical challenge."
Related Ideas
- Cancer ChallengesCancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute · The Road Ahead
- Equal AccessCancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute · The Road Ahead
- Geographic GapsCancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute · Progress Is Real, But Uneven
- Health InequitiesCancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute · Progress Is Real, But Uneven
- Research FundingCancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute · What the Report Means for Immunotherapy
- Research ProgressCancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute · The Road Ahead
- Survival GainsCancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute · Immunotherapy Is Helping Rewrite Survival Curves
- Cancer ProgressCancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute · Progress Is Real, But Uneven